M
Martin S. Tallman
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 948
Citations - 71451
Martin S. Tallman is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 117, co-authored 917 publications receiving 60011 citations. Previous affiliations of Martin S. Tallman include University of Rome Tor Vergata & University of Toronto.
Papers
More filters
Journal ArticleDOI
Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study
Aaron D. Schimmer,Wolfgang Herr,Mathias Hänel,Gautham Borthakur,Arthur E. Frankel,Heinz A. Horst,Sonja Martin,Jeannine Kassis,Pierre Desjardins,Karen Seiter,Walter Fiedler,Richard Noppeney,Aristoteles Giagounidis,Christine Jacob,Jacques Jolivet,Martin S. Tallman,Steffen Koschmieder +16 more
TL;DR: The addition of AEG35156 to reinduction chemotherapy was well tolerated but did not improve rates of remission, and alternative therapeutic strategies should be explored in patients with AML refractory to induction chemotherapy.
Journal ArticleDOI
A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition
Eytan M. Stein,Guillermo Garcia-Manero,David A. Rizzieri,Raoul Tibes,Jesus G. Berdeja,Mojca Jongen-Lavrencic,Jessica K. Altman,Hartmut Döhner,Blythe Thomson,Stephen J. Blakemore,Scott R. Daigle,Greg Fine,Nigel J. Waters,Andrei V Krivstov,Richard Koche,Scott A. Armstrong,Peter T.C. Ho,Bob Löwenberg,Martin S. Tallman +18 more
TL;DR: Pinometostat treatment of MLL-rearranged cells and xenografts reduced histone H3K79 methylation, decreased MLL target gene expression, and induced selective leukemia cell kill in adult patients with relapsed/refractory R/R leukemia.
Journal ArticleDOI
Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer
Angela DeMichele,Robert Gray,Michelle Horn,Jinbo Chen,Richard Aplenc,William P. Vaughan,Martin S. Tallman +6 more
TL;DR: The effect of several common, functional interleukin-6 promoter variants in node-positive breast cancer patients enrolled on a multicenter, cooperative group, adjuvant chemotherapy trial to determine whether these variants were associated with clinical outcome overall and by estrogen receptor tumor phenotype was evaluated.
Journal ArticleDOI
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Tait D. Shanafelt,Xin V. Wang,Curtis A. Hanson,Elisabeth Paietta,Susan O'Brien,Jacqueline C. Barrientos,Diane F. Jelinek,Esteban Braggio,Jose F. Leis,Cong C. Zhang,Steven Coutre,Paul M. Barr,Amanda F. Cashen,Anthony R. Mato,Avina K. Singh,Michael P Mullane,Richard F. Little,Harry P. Erba,Richard Stone,Mark R. Litzow,Martin S. Tallman,Neil E. Kay +21 more
TL;DR: In conclusion, Ibrutinib-rituximab therapy offers superior PFS relative to FCR in both IGHV mutated and unmutated CLL patients as well as superior OS.
Journal ArticleDOI
Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)
Jorge E. Cortes,Martin S. Tallman,Gary J. Schiller,Denise Trone,Guy Gammon,Stuart L. Goldberg,Alexander E. Perl,Jean-Pierre Marie,Giovanni Martinelli,Mark J. Levis +9 more
TL;DR: The data from this Phase 2 study confirm the high degree of activity of quizartinib monotherapy in FLT3-ITD(+) AML pts relapsed/refractory to 2 nd -line treatment or HSCT, and the safety profile is improved specifically decreasing QT prolongation rate at lower doses.